Psychotropic drug-drug interactions involving P-glycoprotein

CNS Drugs

Volumn 26, Issue 11, 2012, Pages 959-973

  Akamine, Yumiko ^a,c   Yasui Furukori, Norio ^b   Ieiri, Ichiro ^c   Uno, Tsukasa ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CLARITHROMYCIN; CLOMIPRAMINE; CLOZAPINE; CYCLOSPORIN A; CYTOCHROME P450; DESIPRAMINE; DULOXETINE; FEXOFENADINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; ITRACONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; PALIPERIDONE; PAROXETINE; PROPAFENONE; PSYCHOTROPIC AGENT; QUETIAPINE; QUINIDINE; RISPERIDONE; RITONAVIR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TALINOLOL; UNINDEXED DRUG; VENLAFAXINE;

ANTICHOLINERGIC EFFECT; ANTICHOLINERGIC SYNDROME; ATAXIA; BLOOD BRAIN BARRIER; CLINICAL STUDY; DIPLOPIA; DROWSINESS; DRUG EFFICACY; DRUG INFORMATION; DRUG INTERACTION; DRUG SAFETY; DYSARTHRIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; GENETIC VARIABILITY; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; NAUSEA; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TRANSPORT; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME; TREMOR; UNSTEADINESS;

ANIMALS; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; P-GLYCOPROTEIN; PSYCHOTROPIC DRUGS; SUBSTRATE SPECIFICITY;

EID: 84873427680     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0008-z     Document Type: Review

References (242)

1. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215-36.
2. Demeule M, Régina A, Jodoin J, et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol. 2002;38:339-48.
3. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther. 2005;77:503-14.
4. Bauer B, Hartz AM, Fricker G, et al. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood). 2005;230:118-27.
5. Löscher W, Potschka H. Blood-brain barrier active efflux transporters: aTP-binding cassette gene family. NeuroRx. 2005;2:86-98.
6. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica. 2001;31:469-97.
7. Schrickx JA, Fink-Gremmels J. Implications of ABC transporters on the disposition of typical veterinary medicinal products. Eur J Pharmacol. 2008;585:510-9.
8. Westphal K, Weinbrenner A, Giessmann T, et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther. 2000;68:6-12.
9. Boyd RA, Stern RH, Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion. J Clin Pharmacol. 2000;40:91-8.
10. Doering W. Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications. N Engl J Med. 1979;301:400-4.
11. Ding R, Tayrouz Y, Riedel KD, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004;76:73-84.
12. Sadeque AJ, Wandel C, He H, et al. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther. 2000;68:231-7.
13. Adenot M, Lahana R. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates. J Chem Inf Comput Sci. 2004;44:239-48.
14. Thuerauf N, Fromm MF. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur Arch Psychiatry Clin Neurosci. 2006;256:281-6.
15. Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain: focus on psychotropic drugs. Eur Neuropsychopharmacol. 2008;18:157-69.
16. Urquhart BL, Kim RB. Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol. 2009;65:1063-70.
17. Moons T, de Roo M, Claes S, et al. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics. 2011;12:1193-211.
18. O'Brien FE, Dinan TG, Griffin BT, et al. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol. 2012;165:289-312.
19. Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7:415-9.
20. Kirschbaum KM, Uhr M, Holthoewer D, et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology. 2010;59:474-9.
21. Kato M, Fukuda T, Serretti A, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:398-404.
22. Roberts RL, Joyce PR, Mulder RT, et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. 2002;2:191-6.
23. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev. 2002;34:47-54.
24. Sandson NB, Armstrong SC, Cozza KL. An overview of psychotropic drug-drug interactions. Psychosomatics. 2005;46:464-94.
25. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab. 2008;9:394-409.
26. Ereshefsky L. Drug-drug interactions with the use of psychotropic medications. CNS Spectr. 2009;14:1-8.
27. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs. Drugs. 2009;69:1777-98.
28. Keltner NL, Moore RL. Biological perspectives psychiatric drug-drug interactions. Perspect Psychiatr Care. 2010;46:244-51.
29. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41-57.
30. Wang EJ, Lew K, Casciano CN, et al. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002;46:160-5.
31. Shimizu M, Uno T, Sugawara K, et al. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol. 2006;61:538-44.
32. Yasui-Furukori N, Saito M, Niioka T, et al. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther Drug Monit. 2007;29:45-8.
33. Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther. 2005;78:520-8.
34. Weiss J, Dormann SM, Martin-Facklam M, et al. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003;305:197-204.
35. El Ela AA, Hartter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds: implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004;56:967-75.
36. Wang JS, Zhu HJ, Markowitz JS, et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology. 2006;187:415-23.
37. Ibrahim S, Peggins J, Knapton A, et al. Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000;295:1276-83.
38. Feng B, Mills JB, Davidson RE, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36:268-75.
39. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry; waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage: forms based on a biopharmaceutics classification system, 2000. http://www.fda.gov/downloads/Drugs/./Guidances/ucm070246.pdf. Accessed 11 May 2012.
40. Elsinga PH, Hendrikse NH, Bart J, et al. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des. 2004;10:1493-503.
41. Hau P, Fabel K, Baumgart U. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high grade glioma. Cancer. 2004;100:1199-207.
42. Gottesman MM, Hrycyna CA, Schoenlein PV, et al. Genetic analysis of the multidrug transporter. Ann Rev Gen. 1995;29:607-49.
43. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA. 1997;94:4028-33.
44. Barrand MA, Robertson KJ, von Weikersthal SF. Comparisons of P-glycoprotein expression in isolated rat brain microvessels and in primary cultures of endothelial cells derived from microvasculature of rat brain, epididymal fat pad and from aorta. FEBS Lett. 1995;374:179-83.
45. Regina A, Koman A, Piciotti M, et al. Mrp1 multidrug resistance- associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem. 1998;7:705-15.
46. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33:165-74.
47. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry. 2003;54:840-6.
48. Saruwatari J, Yasui-Furukori N, Niioka T, et al. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers. J Clin Psychopharmacol. 2012;32:195-9.
49. Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999;27:866-71.
50. Ma JD, Tsunoda SM, Bertino JS, et al. Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation. Clin Pharmacokinet. 2010;49:223-37.
51. Sandson NB. Drug-drug interaction primer: a compendium of case vignettes for the practicing clinician. Washington, DC: American Psychiatric Publishing, Inc.; 2007.
52. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15:125-31.
53. Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71:141-52.
54. Spina E, Pollicino AM, Avenoso A, et al. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit. 1993;15:243-6.
55. Rapeport WG, Coates PE, Dewland PM, et al. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. J Clin Psychiatry. 1996;57(Suppl. 1):16-9.
56. Ruike Z, Junhua C, Wenxing P. In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Hum Psychopharmacol. 2010;25:553-9.
57. Karlsson L, Hiemke C, Carlsson B, et al. Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. Psychopharmacology. 2011;215:367-77.
58. Schweizer E, Thielen RJ, Frazer A. Venlafaxine: a novel antidepressant compound. Expert Opin Investig Drugs. 1997;6:65-78.
59. Gareri P, De Fazio P, Gallelli L, et al. Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation. Ann Pharmacother. 2008;42:434-8.
60. Ujhelyi MR, O'Rangers EA, Fan C, et al. The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine. Clin Pharmacol Ther. 1993;53:38-48.
61. Bachmakov I, Rekersbrink S, Hofmann U, et al. Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2005;371:195-201.
62. Szabo D, Szabo G Jr, Ocsovszki I, et al. Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex vivo. Cancer Lett. 1999;139:115-9.
63. Ejsing TB, Linnet K. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier. Hum Psychopharmacol. 2005;20:149-53.
64. Ejsing TB, Hasselstrom J, Linnet K. The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites. Drug Metabol Drug Interact. 2006;2:139-62.
65. O'Brien FE, Clarke G, Fitzgerald P, et al. Inhibition of P-glycoprotein enhances transport of the antidepressant imipramine across the blood-brain barrier: microdialysis studies in the conscious freely moving rat. Br J Pharmacol. 2012;166:1333-43.
66. Litman T, Druley TE, Stein WD, et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci. 2001;58:931-59.
67. Mulsant BH, Foglia JP, Sweet RA, et al. The effects of perphenazine on the concentration of nortriptyline and its hydroxymetabolites in older patients. J Clin Psychopharmacol. 1997;17:318-21.
68. Desta Z, Kerbusch T, Soukhova N, et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998;285:428-37.
69. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos. 1999;27:1078-84.
70. Shin JG, Kane K, Flockhart DA. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol. 2001;51:45-52.
71. Brøsen K, Gram LF, Klysner R, et al. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol. 1986;30:43-9.
72. Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: an example with amitriptyline and nortriptyline. Ther Drug Monit. 1994;16:1-12.
73. Boulton DW, DeVane CL, Liston HL, et al. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71:163-9.
74. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet. 1996;31:198-214.
75. Miceli JJ, Anziano RJ, Robarge L, et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000;49(Suppl. 1):65S-70S.
76. Ucar M, Neuvonen M, Luurila H, et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol. 2004;59:879-82.
77. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76:192-200.
78. Lü Y, Yan Y, Wang XF. Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. Chin Med J (Engl). 2004;117:1682-6.
79. Owen A, Goldring C, Morgan P, et al. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements. Br J Clin Pharmacol. 2006;62:237-42.
80. Yang HW, Liu HY, Liu X, et al. Increased P-glycoprotein function and level after long-term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci Lett. 2008;434:299-303.
81. Yamada S, Yasui-Furukori N, Akamine Y, et al. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. Ther Drug Monit. 2009;31:764-8.
82. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002;30:795-804.
83. Lombardo L, Pellitteri R, Balazy M, et al. Induction of nuclear receptors and drug resistance in the brain microvascular endothelial cells treated with antiepileptic drugs. Curr Neurovasc Res. 2008;5:82-92.
84. Ott M, Fricker G, Bauer B. Pregnane X receptor (PXR) regulates P-glycoprotein at the blood-brain barrier: functional similarities between pig and human PXR. J Pharmacol Exp Ther. 2009;329:141-9.
85. Baltes S, Fedrowitz M, Tortós CL, et al. Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays. J Pharmacol Exp Ther. 2007;320:331-43.
86. Eyal S, Lamb JG, Smith-Yockman M, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol. 2006;149:250-60.
87. Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos. 2007;35:1032-41.
88. Luna-Tortós C, Fedrowitz M, Löscher W. Several major antiepileptic drugs are substrates for human P-glycoprotein. Neuropharmacology. 2008;55:1364-75.
89. Zhang C, Kwan P, Zuo Z, et al. In vitro concentration dependent transport of phenytoin and phenobarbital, but not ethosuximide, by human P-glycoprotein. Life Sci. 2010;86:899-905.
90. Neerati P, Ganji D, Bedada SK. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats. Eur J Pharm Sci. 2011;44:27-31.
91. Yao D, Yang ZH, Liu L, et al. Verapamil exerts biphasic modulation on phenobarbital transport across the blood-brain barrier: evidence from an in vivo and in vitro study. Naunyn Schmiedebergs Arch Pharmacol. 2011;383:393-402.
92. Moerman L, Wyffels L, Slaets D, et al. Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with (11)C-desmethylloperamide. Epilepsy Res. 2011;94:18-25.
93. Jing X, Liu X, Wen T, et al. Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats. Br J Pharmacol. 2010;159:1511-22.
94. Hung CC, Chen CC, Lin CJ, et al. Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008;18:390-402.
95. Dorado P, López-Torres E, Peñas-Lledó EM, et al. Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms. Pharmacogenomics J. 2012. doi: 10.1038/tpj.2012.19
96. Basic S, Hajnsek S, Bozina N, et al. The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure. 2008;17:524-30.
97. Verschraagen M, Koks CH, Schellens JH, et al. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res. 1999;40:301-6.
98. Lemma GL, Wang Z, Hamman MA, et al. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther. 2006;79:218-30.
99. Yasui-Furukori N, Uno T, Sugawara K, et al. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther. 2005;77:17-23.
100. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry; drug interaction studies: study design, data analysis, implications for dosing, and labeling recommendations, 2012. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 11 May 2012.
101. Wang L, Kitaichi K, Hui CS, et al. Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol. 2000;27:587-93.
102. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther. 1998;64:123-8.
103. Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999;16:408-14.
104. Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther. 2009;86:383-6.
105. Hughes J, Crowe A. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics. J Pharmacol Sci. 2010;113:315-24.
106. Muirhead GJ, Faulkner S, Harness JA, Taubel J. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. Br J Clin Pharmacol. 2002;53(Suppl. 1):37S-43S.
107. Keltner NL, Opara I. Psychotropic drug interactions with grapefruit juice. Perspect Psychiatr Care. 2002;38:31-3.
108. Pawełczyk T, Kłoszewska I. Grapefruit juice interactions with psychotropic drugs: advantages and potential risk. Przegl Lek. 2008;65:92-5.
109. Fuhr U. Drug interactions with grapefruit juice: extent, probable mechanism and clinical relevance. Drug Saf. 1998;18:251-72.
110. Wang EJ, Casciano CN, Clement RP, et al. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res. 2001;18:432-8.
111. Uno T, Yasui-Furukori N. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol. 2006;1:157-61.
112. Garg SK, Kumar N, Bhargava VK, et al. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther. 1998;64:286-8.
113. Hori H, Yoshimura R, Ueda N, et al. Grapefruit juice-fluvoxamine interaction: is it risky or not? J Clin Psychopharmacol. 2003;23:422-4.
114. Ueda N, Yoshimura R, Umene-Nakano W, et al. Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J Biol Psychiatry. 2009;10:832-5.
115. Dürr D, Stieger B, Kullak-Ublick GA, et al. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000;68:598-604.
116. Wang Z, Hamman MA, Huang SM, et al. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002;71:414-20.
117. Dresser GK, Schwarz UI, Wilkinson GR, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther. 2003;73:41-50.
118. Wang XD, Li JL, Su QB, et al. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. Br J Clin Pharmacol. 2009;67:255-61.
119. Markowitz JS, Donovan JL, DeVane CL, et al. Drug interactions with St. John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther. 2004;42:139-48.
120. Zhou S, Chan E, Pan SQ, et al. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol. 2004;18:262-76.
121. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276:14581-7.
122. Hamman MA, Bruce MA, Haehner-Daniels BD, et al. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther. 2001;69:114-21.
123. Asghar A, Gorski JC, Haehner-Daniels B, et al. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. Drug Metab Dispos. 2002;30:20-6.
124. Finch CK, Chrisman CR, Baciewicz AM, et al. Rifampin and rifabutin drug interactions: an update. Arch Intern Med. 2002;162:985-92.
125. Lin JH. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol. 2007;3:81-92.
126. Kim KA, Park PW, Liu KH, et al. Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol. 2008;48:66-72.
127. Holthoewer D, Hiemke C, Schmitt U. Induction of drug transporters alters disposition of risperidone: a study in mice. Pharmaceutics. 2010;2:258-74.
128. de Klerk OL, Willemsen AT, Bosker FJ, et al. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function. Psychiatry Res. 2010;183:151-6.
129. Langer O, Bauer M, Hammers A, et al. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia. 2007;48:1774-84.
130. Clarke G, O'Mahony SM, Cryan JF, et al. Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter? Hum Psychopharmacol. 2009;24:217-23.
131. Philip NS, Carpenter LL, Tyrka AR, et al. Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother. 2010;11:709-22.
132. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;58:693-705.
133. Alvarez AI, Real R, Pérez M, et al. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci. 2010;99:598-617.
134. Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. Curr Drug Targets. 2011;12:600-20.
135. Nicolazzo JA, Katneni K. Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr Top Med Chem. 2009;9:130-47.
136. Ni Z, Bikadi Z, Rosenberg MF, et al. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab. 2010;11:603-17.
137. Wang JS, Zhu HJ, Markowitz JS, et al. Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol. 2008;103:336-41.
138. Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60:196-209.
139. He SM, Li R, Kanwar JR, et al. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Curr Med Chem. 2011;18:439-81.
140. Okamura T, Kikuchi T, Irie T. PET imaging of MRP1 function in the living brain: method development and future perspectives. Curr Top Med Chem. 2010;10:1810-9.
141. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 2000;22:380-7.
142. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP2C19 and 3A4. J Clin Pharmacol. 1998;38:112-21.
143. Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptyline oxide in man. Drug Metab Rev. 2004;36:723-46.
144. Thieme D, Rolf B, Sachs H, et al. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med. 2008;122:149-55.
145. Wen B, Ma L, Zhu M. Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008;173:59-67.
146. Uhr M, Grauer MT. Abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res. 2003;37:179-85.
147. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry. 1999;46:839-49.
148. Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol. 2001;11:275-83.
149. Fudio S, Borobia AM, Piñana E, et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol. 2010;626:200-4.
150. Yin OQ, Wing YK, Cheung Y, et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol. 2006;26:367-72.
151. Perroud N, Bondolfi G, Uher R, et al. Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample. Pharmacogenomics. 2011;12:365-77.
152. Nielsen KK, Flinois JP, Beaune P, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther. 1996;277:1659-64.
153. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151:737-48.
154. Margolis JM, O'Donnell JP, Mankowski DC, et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28:1187-91.
155. Liu ZQ, Shu Y, Huang SL, et al. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin. 2001;22:85-90.
156. Scordo MG, Spina E, Dahl ML, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol. 2005;97:296-301.
157. Katoh Y, Uchida S, Kawai M, et al. Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol Pharm Bull. 2010;33:285-8.
158. Miura M, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine. Xenobiotica. 2007;37:169-79.
159. Wang JS, Wang W, Xie HG, et al. Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. Br J Clin Pharmacol. 1997;44:195-8.
160. Madsen H, Nielsen KK, Brøsen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms: a population study. Br J Clin Pharmacol. 1995;39:433-9.
161. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol. 1999;39:567-77.
162. Kvist EE, Al-Shurbaji A, Dahl ML, et al. Quantitative pharmacogenetics of nortriptyline: a novel approach. Clin Pharmacokinet. 2001;40:869-77.
163. Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos. 1997;25:740-4.
164. Feng Y, Pollock BG, Ferrell RE, et al. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol. 2006;61:558-69.
165. Jornil J, Jensen KG, Larsen F, et al. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010;38:376-85.
166. Ververs FF, Voorbij HA, Zwarts P, et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet. 2009;48:677-83.
167. Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline N-demethylation is catalyzed by multiple soforms of human cytochrome P-450 in vitro. Drug Metab Dispos. 1999;27:763-6.
168. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005;33:262-70.
169. Wang JH, Liu ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001;70:42-7.
170. Eap CB, Bender S, Gastpar M, et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit. 2000;22:209-14.
171. Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology. 1999;20:480-90.
172. McAlpine DE, Biernacka JM, Mrazek DA, et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit. 2011;33:14-20.
173. Wang JS, Zhu HJ, Donovan JL, et al. Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res. 2009;110:90-4.
174. Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol. 2007;63:1147-51.
175. Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit. 2009;31:233-8.
176. Wójcikowski J, Boksa J, Daniel WA. Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver: a comparison with other phenothiazines. Biochem Pharmacol. 2010;80:1252-9.
177. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44:439-46.
178. Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol. 2001;41:823-32.
179. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48:761-804.
180. Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37:435-56.
181. Brockmöller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther. 2002;72:438-52.
182. Tateishi T, Watanabe M, Kumai T, et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000;67:2913-20.
183. Bagli M, Höflich G, Rao ML, et al. Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. Int J Clin Pharmacol Ther. 1995;33:646-52.
184. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-93.
185. de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics. 2010;51:80-8.
186. Invega [package insert]. Titusville: Janssen Pharmaceuticals; 2011.
187. Masui T, Kusumi I, Takahashi Y, et al. Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006;28:73-5.
188. Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000;50:563-71.
189. Aklillu E, Kalow W, Endrenyi L, et al. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics. 2007;17:989-93.
190. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509-22.
191. Bakken GV, Rudberg I, Christensen H, et al. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009;37:254-8.
192. Bork JA, Rogers T, Wedlund PJ, et al. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry. 1999;60:469-76.
193. Xiang Q, Zhao X, Zhou Y, et al. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol. 2010;50:659-66.
194. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. NeuroReport. 2001;12:3557-60.
195. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol. 1994;47:1969-79.
196. Park PW, Seo YH, Ahn JY, et al. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther. 2009;34:569-74.
197. Potschka H, Fedrowitz M, Löscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett. 2002;327:173-6.
198. Chen H, Grover S, Yu L, et al. Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. Chem Res Toxicol. 2010;23:159-70.
199. Reidenberg GD, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther. 1995;58:279-87.
200. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32:554-63.
201. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000;55:821-5.
202. Komatsu T, Yamazaki H, Asahi S, et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos. 2000;28:1361-8.
203. Cottencin O, Regnaut N, Thevenon-Gignac C, et al. Carbamazepine- fluvoxamine interaction: consequences for the carbamazepine plasma level. Encephale. 1995;21:141-5.
204. Conus P, Bondolfi G, Eap CB, et al. Pharmacokinetic fluvoxamine- clomipramine interaction with favorable therapeutic consequences in therapy-resistant depressive patient. Harmacopsychiatry. 1996;29:108-10.
205. Wagner W, Vause EW. Fluvoxamine: a review of global drug-drug interaction data. Clin Pharmacokinet. 1995;29:26-32.
206. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 1994;16:368-74.
207. Yasui-Furukori N, Kondo T, Mihara K, Inoue Y, Kaneko S. Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Psychopharmacology. 2004;171:223-7.
208. Chiu CC, Lane HY, Huang MC, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol. 2004;44:1385-90.
209. Albers LJ, Reist C, Helmeste D, et al. Paroxetine shifts imipramine metabolism. Psychiatry Res. 1996;59:189-96.
210. Saito M, Yasui-Furukori N, Nakagami T, et al. Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol. 2005;25:527-32.
211. Wolfsperger M, Greil W. Galactorrhea during treatment with trimipramine: a case report. Pharmacopsychiatry. 2005;38:326-7.
212. Gélisse P, Hillaire-Buys D, Halaili E, et al. Carbamazepine and clarithromycin: a clinically relevant drug interaction. Rev Neurol (Paris). 2007;163:1096-9.
213. von Rosensteil NA, Adam D. Macrolide antibacterials: drug interactions of clinical significance. Drug Saf. 1995;13:105-22.
214. Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine. Pharmacopsychiatry. 2008;41:258-9.
215. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet. 2005;20:55-64.
216. Yasui N, Kondo T, Otani K, et al. Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism. J Clin Psychopharmacol. 1999;19:149-54.
217. Skarke C, Jarrar M, Erb K, et al. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther. 2003;74:303-11.
218. Abilify [package insert]. Princeton: Bristol-Myers-Squibb; 2005.
219. Brøsen K, Gram LF. Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. Eur J Clin Pharmacol. 1989;37:155-60.
220. Pfandl B, Mörike K, Winne D, et al. Stereoselective inhibition of nortriptyline hydroxylation in man by quinidine. Xenobiotica. 1992;22:721-30.
221. van Heeswijk RP, Bourbeau M, Campbell P, et al. Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol. 2006;46:758-67.
222. Aung GL, O'Brien JG, Tien PG, et al. Increased aripiprazole concentrations in an HIV-positive male concurrently taking duloxetine, darunavir, and ritonavir. Ann Pharmacother. 2010;44:1850-4.
223. Bates DE, Herman RJ. Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir. Ann Pharmacother. 2006;40:1190-5.
224. Pollack TM, McCoy C, Stead W. Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients. Pharmacotherapy. 2009;29:1386-91.
225. Jover F, Cuadrado JM, Andreu L, et al. Reversible coma caused by risperidone-ritonavir interaction. Clin Neuropharmacol. 2002;25:251-3.
226. Kelly DV, Béïque LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother. 2002;36:827-30.
227. Beattie B, Biller J, Mehlhaus B, et al. Verapamil-induced carbamazepine neurotoxicity: a report of two cases. Eur Neurol. 1988;28:104-5.
228. Hermann DJ, Krol TF, Dukes GE, et al. Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine. J Clin Pharmacol. 1992;32:176-83.
229. Nakagami T, Yasui-Furukori N, Saito M, et al. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther. 2005;78:43-51.
230. Nakamura A, Mihara K, Nagai G, et al. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther Drug Monit. 2009;31:575-8.
231. Steinacher L, Vandel P, Zullino DF, et al. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol. 2002;12:255-60.
232. Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-induced changes in plasma levels of neuroleptics. Pharmacopsychiatry. 1995;28:26-8.
233. Yasui-Furukori N, Kondo T, Mihara K, et al. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. J Clin Psychopharmacol. 2003;23:435-40.
234. Brown CS, Wells BG, Cold JA, et al. Possible influence of carbamazepine on plasma imipramine concentrations in children with attention deficit hyperactivity disorder. J Clin Psychopharmacol. 1990;10:359-62.
235. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology. 2002;162:50-4.
236. Grimm SW, Richtand NM, Winter HR, et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol. 2006;61:58-69.
237. Joos A, Frank U, Kaschka W. Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with atypical mycobacterial infection [letter]. J Clin Psychopharmacol. 1998;18:83-5.
238. Kim YH, Cha IJ, Shim JC, et al. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. J Clin Psychopharmacol. 1996;16:247-52.
239. Bebchuk JM, Stewart DE. Drug interaction between rifampin and nortriptyline: a case report. Int J Psychiatry Med. 1991;21:183-7.
240. Misra LK, Erpenbach JE, Hamlyn H, et al. Quetiapine: a new atypical antipsychotic. S D J Med. 1998;51:189-93.
241. Johne A, Schmider J, Brockmöller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol. 2002;22:46-54.
242. Van Strater AC, Bogers JP. Interaction of St John's wort (Hypericum perforatum) with clozapine. Int Clin Psychopharmacol. 2012;27:121-4.